Streamlined Synthetic Amniotic Membrane for Ocular Penetrating Injuries and Burns: Simplified Logistics, No Special Storage, Extended Shelf Life

In end-user discovery with the 59 MDW and C-STARS, Matregenix confirmed that current biological materials for treating ocular trauma face challenges in cost, handling, and shelf life. To address these issues, Matregenix will develop MatriNova for ocular trauma, which will reduce costs by at least 50% compared to the current standard, provide 20 times greater tensile strength, and extend shelf life by 300%. In Phase II, Matregenix will design a version of MatriNova that is most ideal for treating ocular trauma in the Air Force in battlefield and forward-deployed austere environments (adjusting pore size, structure), then perform in vitro and in vivo studies to advance MatriNova to FDA 510(k) submission.  The study will test MatriNova’s structural support capability for healing penetrating mechanical eye injuries (like from shrapnel or projectile) as well as MatriNova’s tissue regeneration capability on the surface of the eye in cases of burn or thermal injury. Demonstrating the efficiency of these two use cases for MatriNova ocular trauma repair in animals will show MatriNova’s ability to heal the two most common and difficult types of eye injuries in military service members compared to the state-of-the-art solutions and prepare the product for in-human testing.